Whit Bernard, Metsera CEO
Metsera outlines $250M IPO plans as obesity biotech competition rises
Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO.
That would be the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
